Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk comman

Six dividend stocks in a $500,000 portfolio sound like a solid income plan, but where you hold them

JP Morgan analyst Chris Schott maintains Pfizer (NYSE:PFE) with a Neutral and raises the price ta

A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRN

Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason

Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the

Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targ

Four household names are dangling yields above 5% at a moment when their earnings, cash flow, and de

Pfizer's stronger non-COVID outlook more than offsets lower COVID revenue expectations, although ful

Sapient Capital LLC cut its position in shares of Pfizer Inc. (NYSE: PFE) by 93.6% in the third quar

Bristol Myers Squibb maintains a robust portfolio in oncology and hematology with a focus on special

PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage p

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combinati

Pfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, e

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quar

Pfizer has existed for more than 100 years.  The company has a long history of successfully developi

When the paycheck stops at retirement, your portfolio has to carry the weight, and one dividend cut

Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risk

Cantor Fitzgerald analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Neutral and raises the

PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its au

Pfizer is racing towards important patent cliffs. However, the company's new and acquired products,

The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc.'s (NYSE:PFE) TUKYSA (t

The FDA approved Pfizer's TUKYSA combination as a front-line maintenance therapy for advanced HE

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median pro

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Admin

Pfizer will cut around 330 jobs in Italy at its Sicily plant, ​labour unions said on Wednesday, maki

Pfizer Inc. (NYSE: PFE - Get Free Report) declared a quarterly dividend on Tuesday, October 6th. Sto

Some of the most recognizable dividend stocks in the market have been paying shareholders with money

–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanc

Pfizer Inc. (PFE, Financials) is retaining its quarterly dividend at 43 cents a share, sustaining on

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard

A couple of the stocks on this list pay more than 6% in dividends.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors decla

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have si

Pfizer's stock has been struggling for multiple years, and it trades at a low valuation. Its dividen

Florida files a lawsuit against Pfizer and CEO Albert Bourla over alleged deceptive vaccine marketin

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenge

J&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's che

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the la

Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting th

Eli Lilly's dominance in metabolic health through blockbuster weight-loss drugs. Pfizer's pivot towa

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfiz

Energy Transfer is a midstream leader with an especially juicy distribution. Pfizer is committed to

Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.  Pfizer hasn't en

Three struggling companies keep sending dividend checks while investors wait for their repairs to ki

Pfizer shares have underperformed since 2021, with the recent poor performance reflecting concerns a

There are blazing deals for some of the top healthcare stocks -- companies with proven track records